A dynamic opening discussion featuring CEOs and founders at the forefront of innate immunity and NK-cell innovation. This high-level session sets the tone for the meeting as industry leaders examine the current landscape, emerging scientific and commercial inflection points, and the path to translating innate immune breakthroughs into meaningful therapeutic impact. Through candid insights and forward-looking perspectives, the panel will outline the opportunities, challenges, and decisive moves that will shape the field over the next 3–5 years.

• The milestones that brought innate therapies to today’s inflection point
• What’s driving the next wave of NK and innate innovation
• Scientific and clinical hurdles that must be overcome
• Strategic priorities in a shifting funding and regulatory climate
• Commercial pathways and competitive positioning for the next era